Skip to main content
. 2014 Oct 15;24(6):791–801. doi: 10.1089/scd.2014.0174

FIG. 3.

FIG. 3.

AdIGF-I-MSCs treatment reduces the activation of hepatic stellate cells (HSCs). (A) Analysis of mRNA levels of transforming growth factor-beta 1 (TGF-β1), α-SMA, and collagen 1A2 (COL1A2) at 14 days after MSCs application. (B) Quantitative graphs showing mRNA expression levels of TGF-β1, α-SMA, and COL1A2 in HSCs after 40 h of incubation with Dulbecco's modified Eagle's medium (DMEM) (control) and supernatants of AdIGF-I-MSCs or AdGFP-MSCs. (C) Quantitative graphs showing active TGF-β1 and α-SMA protein expression levels in HSCs after 40 h of incubation with DMEM (control) and supernatants of AdIGF-I-MSCs or AdGFP-MSCs. TGF-β1 was measured at 48 h after incubation *σP<0.05; **σσP<0.01; ***σσσP<0.001; * versus saline; σ versus AdGFP-MSCs; ****P<0.0001 versus DMEM. sn, supernatant.